Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...6364656667686970717273...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. (Pubmed Central) -  Mar 27, 2021   
    In this scenario, anti-EGFR targeted agent cetuximab, introduced in clinical practice a decade ago, represents the only approved targeted therapy to date, while the development of immune-checkpoint inhibitors has recently changed the available treatment options. In this review, we focus on the current role of anti-EGFR therapies in HNCs, underlying available clinical data and mechanisms of resistance, and highlight future perspectives regarding their role in the era of immunotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    P2 data, Journal:  Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. (Pubmed Central) -  Mar 25, 2021   
    In this review, we focus on the current role of anti-EGFR therapies in HNCs, underlying available clinical data and mechanisms of resistance, and highlight future perspectives regarding their role in the era of immunotherapy. Irinotecan plus cetuximab rechallenge as third-line treatment for KRAS wild-type mCRC was safe and had promising activity, especially in those with a long CFI, warranting further investigation in a Phase 3 randomised trial.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Gold nanoparticles enhance fluorescence signals by flow cytometry at low antibody concentrations. (Pubmed Central) -  Mar 24, 2021   
    In this work we constructed a nanoprobe using gold nanoparticles coated with primary antibody Cetuximab...Our results showed an enhanced fluorescent signal likely due to the proximity between the extinction coefficient of gold nanoparticles and the emission peak of Alexa Fluor 488, at exceptionally low concentrations, occurring within a high level of specificity. Moreover, the nanoprobe did not alter the cellular viability suggesting gold nanoparticles as a feasible approach for cell labelling using low concentrations of secondary antibodies for routine flow cytometry applications.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date, Trial primary completion date:  INFIELD: Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) -  Mar 24, 2021   
    P2,  N=72, Completed, 
    Moreover, the nanoprobe did not alter the cellular viability suggesting gold nanoparticles as a feasible approach for cell labelling using low concentrations of secondary antibodies for routine flow cytometry applications. Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> Mar 2021 | Trial primary completion date: Dec 2021 --> Dec 2020
  • ||||||||||  PF-07284892 / Pfizer
    Enrollment open, Combination therapy, Metastases:  PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 23, 2021   
    P1,  N=70, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> Mar 2021 | Trial primary completion date: Dec 2021 --> Dec 2020 Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal:  Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy. (Pubmed Central) -  Mar 23, 2021   
    Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. (Pubmed Central) -  Mar 23, 2021   
    The CA was evaluated in combination with PNA-labelled trastuzumab, T-ZHP1, for radionuclide HER2 pretargeting...Injection of the CA 6 h post injection of the radiolabeled primary agent [I]I-T-ZHP1 gave a moderate reduction of the radioactivity concentration in the blood after 1 h from 8.5 ± 1.8 to 6.0 ± 0.4%ID/g. These proof-of-principle results could guide future development of a more efficient CA.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. (Pubmed Central) -  Mar 23, 2021   
    Exploiting knowledge of the mechanisms of resistance to BRAF inhibitors has been crucial to developing effective therapeutic strategies in BRAF-V600E mutant mCRC. The BEACON trial is a successful example of this approach, using encorafenib and cetuximab with or without binimetinib in patients with previously treated BRAF V600E mutant mCRC, showing an impressive improvement in clinical outcomes and tolerable toxicity compared with chemotherapy, establishing a new standard of care in this setting.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  ADAM17-EGFR signaling contributes to oral cancer pain. (Pubmed Central) -  Mar 20, 2021   
    We infer from these data that ADAM17-EGFR signaling is involved in cancer mediator-induced nociception. The differentially expressed genes and their secreted protein products may serve as candidate therapeutic targets for oral cancer pain and warrant further evaluation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Metastases:  FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) -  Mar 19, 2021   
    P2,  N=10, Recruiting, 
    The differentially expressed genes and their secreted protein products may serve as candidate therapeutic targets for oral cancer pain and warrant further evaluation. Trial completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Platinum-Based Regimens Versus Cetuximab in Definitive Chemoradiation for Human Papillomavirus-Unrelated Head and Neck Cancer. (Pubmed Central) -  Mar 18, 2021   
    Carboplatin-based chemoradiation (CB-CRT) is another option; however, relative efficacies of CP-CRT, CB-CRT and C225-RT are unclear, particularly in the human papillomavirus (HPV)-unrelated population...Propensity matching confirmed reduced hazards with a combined CP/CB-CRT group compared with C225-RT for LRF: HR 0.384, (P=0.018) and OS: HR 0.557 (P=0.045) and CB-CRT group compared to C225-RT for LRF: HR 0.427 (P=0.023). In conclusion, CB-CRT is an effective alternative to CP-CRT in HPV-unrelated LA-HNSCC with superior locoregional control and OS compared to C225-RT.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. (Pubmed Central) -  Mar 17, 2021   
    MGO scavengers inhibit AKT and resensitize KRAS-mutated CRC cells to cetuximab in vivo. This study establishes a link between MGO and AKT activation and pinpoints this oncometabolite as a potential target to tackle EGFR-targeted therapy resistance in CRC.
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial primary completion date, Metastases:  CAVE: Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 17, 2021   
    P2,  N=77, Active, not recruiting, 
    This study establishes a link between MGO and AKT activation and pinpoints this oncometabolite as a potential target to tackle EGFR-targeted therapy resistance in CRC. Trial primary completion date: Feb 2021 --> Jun 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, HEOR:  Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. (Pubmed Central) -  Mar 16, 2021   
    This study found that doublet therapy for metastatic BRAF variant colorectal cancer was unlikely to be cost-effective under current pricing. Cost-effectiveness needs to be considered in clinical trial design, particularly when combining new therapies with non-cost-effective treatments that are coadministered without a fixed duration.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting. (Pubmed Central) -  Mar 16, 2021   
    Results show that neither tumor delivery nor selectivity (tumor-to-normal ratio) of cetuximab and IRDye conjugated tNLs correlate with EGFR expression in U251, U87 and 9L tumors, and in fact underrepresent their imaging-derived molecular specificity by up to 94.2%...This study provides a unique opportunity to address the problematic disconnect between tNL synthesis and in vivo specificity. The findings encourage their continued adoption as platforms for precision medicine, and facilitates intelligent synthesis and patient customization in order to improve safety profiles and therapeutic outcomes.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. (Pubmed Central) -  Mar 16, 2021   
    Despite our better understanding of HNSCC biology, no other molecular-targeted agent has been approved for HNSCC. In this review, we outline the mechanisms of resistance to the therapeutic strategies currently used in HNSCC, discuss combination treatment strategies to overcome them, and summarize the therapeutic regimens that are presently being evaluated in early- and late-phase clinical trials.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis. (Pubmed Central) -  Mar 16, 2021   
    Cetuximab plus chemotherapy has exact efficacy in treating mCRC, and it results in a higher long-term survival rate and a lower disease progression rate than chemotherapy alone, improves the quality of life of patients and produces tolerable adverse reactions. Besides, poor tumor differentiation is an independent risk factor for the mPFS and mOS of patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] ROLE OF MET AND RON ACTIVATION IN CETUXIMAB RESISTANCE IN COLORECTAL CANCER (DDW Virtual) -  Mar 15, 2021 - Abstract #DDW2021DDW_3312;    
    A comparative RNA-seq analysis showed that PDXs with high pMET/pRON levels could be segregated from PDXs with low pMET/pRON levels. Differential response of these PDXs and their organoid (PDO) derivatives for cetuximab resistance and response to crizotinib addition based on their pMET/pRON levels will be presented.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial termination, Metastases:  Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 15, 2021   
    P=N/A,  N=3, Terminated, 
    Differential response of these PDXs and their organoid (PDO) derivatives for cetuximab resistance and response to crizotinib addition based on their pMET/pRON levels will be presented. N=11 --> 3 | Completed --> Terminated; Slow accrual
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Falcon-X 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy () -  Mar 13, 2021 - Abstract #AACR2021AACR_4204;    
    For CRC PDX tumors, Oxaliplatin, Cetuximab, 5-FU, Bevacizumab (anti-VEGF), and Pembrolizumab (anti-PD1) were assayed; for RCC: Sunitinib, Pazopanib, Temsirolimus, Bevacizumab, and Pembrolizumab; for NSCLC: Docetaxel, Cisplatin, Afatinib, Atezolizumab (anti-PDL1), and Pembrolizumab...Such a platform is potentially suitable for cancer drug discovery and clinical decision making for screening cancer therapeutic efficacy. Further studies include identifying cytokines that modulate the immune response to fibroblast co-culture, expanding the approach to other solid tumor types such as breast, brain, sarcoma, and melanoma, as well as screening novel immunotherapy agents.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] A Conversation with the Investigators: Perspectives on the Management of Head and Neck Cancer () -  Mar 12, 2021 - Abstract #ASCO2021ASCO_155;    
    Appreciate available Phase III findings supporting the FDA approval of pembrolizumab as first-line therapy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), in combination with platinum-based chemotherapy or as monotherapy in those with PD-L1-positive tumors, and consider the effect of this information on current and future clinical practice...Recognize the recent FDA approval of a new dosage regimen for cetuximab for patients with SCCHN and identify patients who are appropriate candidates for this new regimen Consider the clinical relevance of the presence of NTRK gene fusions in salivary gland carcinomas, and appreciate available clinical research evidence with and FDA endorsements for larotrectinib and entrectinib in patients with NTRK fusion-positive tumors in order to appropriately select therapy for individuals harboring these abnormalities...Recollect oncogenic pathways (e.g., PD-1/PD-L1, HRAS, NTRK, inhibitors of apoptosis proteins) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets. Recall the design of ongoing clinical trials evaluating novel agents and strategies in SCCHN, and counsel appropriate patients about availability and participation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma. (Pubmed Central) -  Mar 12, 2021   
    A new systemic therapy, cemiplimab, has been approved for the treatment of locally advanced and metastatic cSCC. In the present review, we provide recommendations for patient classification and staging based on current guidelines, direction for determining patient eligibility for surgery and RT, and an overview of the available systemic treatment options for advanced cSCC and of the benefits of a multidisciplinary approach to patient management.